In the primary efficacy analysis , mean percent change in UACR from baseline was 173 % ( 95 % CI 3365 to 094 ) for 158 patients in the eplerenone group compared with 103 % ( 675 to 223 ) for 146 patients in the placebo group ( absolute difference 276 % [ 5115 to 396 ] ; p = 00222 ) .